These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34825103)

  • 1. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence.
    Schultheis A; Sanchez M; Pedersen S; Kyriakides T; Ho YC; Kluger Y; Springer SA
    Contemp Clin Trials Commun; 2021 Dec; 24():100866. PubMed ID: 34825103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder.
    Biondi BE; Mohanty S; Wyk BV; Montgomery RR; Shaw AC; Springer SA
    Contemp Clin Trials Commun; 2021 Mar; 21():100704. PubMed ID: 33490708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations when prescribing opioid agonist therapies for people living with HIV.
    Tarfa A; Lier AJ; Shenoi SV; Springer SA
    Expert Rev Clin Pharmacol; 2024 Jul; 17(7):549-564. PubMed ID: 38946101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
    Fanucchi L; Springer SA; Korthuis PT
    Curr HIV/AIDS Rep; 2019 Feb; 16(1):1-6. PubMed ID: 30684117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
    Cook RR; Torralva R; King C; Lum PJ; Tookes H; Foot C; Vergara-Rodriguez P; Rodriguez A; Fanucchi L; Lucas GM; Waddell EN; Korthuis PT
    Drug Alcohol Depend; 2021 Nov; 228():109077. PubMed ID: 34600253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder.
    Dever JA; Hertz MF; Dunlap LJ; Richardson JS; Wolicki SB; Biggers BB; Edlund MJ; Bohm MK; Turcios D; Jiang X; Zhou H; Evans ME; Guy GP
    Public Health Rep; 2024; 139(4):484-493. PubMed ID: 38268479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
    Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
    Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
    Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort.
    McCann NC; LaRochelle MR; Morgan JR
    J Subst Use Addict Treat; 2024 Apr; 159():209281. PubMed ID: 38122988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Impact of HIV Serostatus on the Hepatitis C Virus Care Cascade and Injection Drug Use Among Persons Initiating Medication Treatment for Opioid Use Disorder.
    Lier AJ; Vander Wyk B; Di Paola A; Springer SA
    Open Forum Infect Dis; 2022 Nov; 9(11):ofac624. PubMed ID: 36467300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.